Skip to content

Zymeworks ZYME Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$9.18M
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$486K-52.2%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$17.03M-0.4%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's lease liability payments - due year two?
Zymeworks (ZYME) reported lease liability payments - due year two of $3.84M in Q1 2026.
How has Zymeworks's lease liability payments - due year two changed year-over-year?
Zymeworks's lease liability payments - due year two increased by 4.8% year-over-year, from $3.66M to $3.84M.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.